CA2863243A1 - Analogue de la rapamycine et procedes de fabrication associes - Google Patents

Analogue de la rapamycine et procedes de fabrication associes Download PDF

Info

Publication number
CA2863243A1
CA2863243A1 CA2863243A CA2863243A CA2863243A1 CA 2863243 A1 CA2863243 A1 CA 2863243A1 CA 2863243 A CA2863243 A CA 2863243A CA 2863243 A CA2863243 A CA 2863243A CA 2863243 A1 CA2863243 A1 CA 2863243A1
Authority
CA
Canada
Prior art keywords
cancer
compound
mmol
substituted
immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2863243A
Other languages
English (en)
Inventor
Bing Wang
Jonathon Zhong Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HANGZHOU ZYLOX PHARMA Co Ltd
Original Assignee
HANGZHOU ZYLOX PHARMA Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HANGZHOU ZYLOX PHARMA Co Ltd filed Critical HANGZHOU ZYLOX PHARMA Co Ltd
Publication of CA2863243A1 publication Critical patent/CA2863243A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2863243A 2012-11-30 2012-11-30 Analogue de la rapamycine et procedes de fabrication associes Abandoned CA2863243A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2012/085631 WO2014082286A1 (fr) 2012-11-30 2012-11-30 Analogue de la rapamycine et procédés de fabrication associés

Publications (1)

Publication Number Publication Date
CA2863243A1 true CA2863243A1 (fr) 2014-06-05

Family

ID=50827071

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2863243A Abandoned CA2863243A1 (fr) 2012-11-30 2012-11-30 Analogue de la rapamycine et procedes de fabrication associes

Country Status (9)

Country Link
EP (1) EP2809675A4 (fr)
JP (1) JP2016500112A (fr)
KR (1) KR20150003156A (fr)
CN (1) CN104854112A (fr)
AU (1) AU2012395673A1 (fr)
CA (1) CA2863243A1 (fr)
SG (1) SG11201404432QA (fr)
WO (1) WO2014082286A1 (fr)
ZA (1) ZA201405746B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104327097B (zh) * 2014-10-11 2017-02-08 福建省微生物研究所 雷帕霉素的三氮唑衍生物和用途
CN104341434B (zh) * 2014-10-16 2016-04-06 福建省微生物研究所 取代的雷帕霉素三氮唑衍生物和用途
CN104557975B (zh) * 2014-12-23 2017-06-20 连云港恒运医药有限公司 依维莫司中间体及其降解杂质的制备方法
PL3061765T3 (pl) * 2015-02-27 2018-07-31 Warszawski Uniwersytet Medyczny Pochodna protoescygeniny, sposób jej otrzymywania, zastosowanie i użycie w kompozycjach farmaceutycznych zawierających ten związek
CN104876944B (zh) * 2015-05-13 2017-11-10 普济生物科技（台州）有限公司 一种依维莫司的制备方法
EP3109250A1 (fr) * 2015-06-23 2016-12-28 Synbias Pharma AG Procede pour la synthese de derives de rapamycine
WO2017038925A1 (fr) * 2015-09-03 2017-03-09 日本化薬株式会社 Composition pharmaceutique contenant de la rapamycine ou un dérivé de celle-ci
CN105481704A (zh) * 2016-01-12 2016-04-13 西安近代化学研究所 一种键合剂n-炔丙基二乙醇胺的合成与提纯方法
CN107759616B (zh) * 2016-08-23 2020-11-17 上海微创医疗器械（集团）有限公司 一种化合物及其制备方法和用途
TWI836643B (zh) * 2017-04-05 2024-03-21 哈佛大學校長及研究員協會 巨環化合物及其用途
JP7348071B2 (ja) * 2017-05-02 2023-09-20 レヴォリューション・メディスンズ，インコーポレイテッド ｍＴＯＲ阻害剤としてのラパマイシン類似体
CN109776569A (zh) * 2017-11-14 2019-05-21 上海医药工业研究院 一种依维莫司的制备方法
CN108484637A (zh) * 2018-03-13 2018-09-04 福建省微生物研究所 靶向抗癌新药x-76成盐化合物及其用途、制备方法
IL300091A (en) 2018-05-01 2023-03-01 Revolution Medicines Inc C40-, C28-, and C-32-linked rapamycin analogs as MTOR inhibitors
EP3788050B1 (fr) 2018-05-01 2024-08-28 Revolution Medicines, Inc. Analogues de rapamycine liés à c26 utilisés en tant qu'inhibiteurs de mtor
CN109776571B (zh) * 2019-01-31 2021-06-11 哈药慈航制药股份有限公司 一种雷帕霉素类似物及其制备方法和应用
CN112057425A (zh) * 2020-09-30 2020-12-11 严鹏科 一种雷帕霉素制剂及其制备方法
CN115160343B (zh) * 2022-06-09 2023-11-14 福建省微生物研究所 一种雷帕霉素衍生物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
AU4246197A (en) * 1996-09-09 1998-03-26 American Home Products Corporation Rapamycin derivatives with unnatural stereochemistries
JP2001500126A (ja) * 1996-09-09 2001-01-09 アメリカン・ホーム・プロダクツ・コーポレイション アルキル化ラパマイシン誘導体
TW557297B (en) * 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same

Also Published As

Publication number Publication date
KR20150003156A (ko) 2015-01-08
WO2014082286A1 (fr) 2014-06-05
ZA201405746B (en) 2015-11-25
AU2012395673A1 (en) 2014-08-14
EP2809675A1 (fr) 2014-12-10
EP2809675A4 (fr) 2015-08-12
SG11201404432QA (en) 2014-10-30
JP2016500112A (ja) 2016-01-07
CN104854112A (zh) 2015-08-19
WO2014082286A9 (fr) 2014-11-13
AU2012395673A8 (en) 2015-06-11

Similar Documents

Publication Publication Date Title
CA2863243A1 (fr) Analogue de la rapamycine et procedes de fabrication associes
PL191212B1 (pl) Analog rapamycyny zawierający tetrazol oraz jego zastosowanie
EP1832592A2 (fr) Isomères 15-C de rapamycine et de rapamycine 42-C EPI, leur procédé de fabrication et leur utilisation
US7622477B2 (en) Isomers and 42-epimers of rapamycin alkyl ether analogs, methods of making and using the same
US7678901B2 (en) Rapamycin analogs containing an antioxidant moiety
US20070203171A1 (en) Combination of rapamycin and its tetrazole isomers and epimers, methods of making and using the same
US5604234A (en) Substituted thiol macrolactam immunomodulators
WO1994021644A1 (fr) Immunomodulateurs sous forme de macrolactames thio-heterocycliques
EP1826212A1 (fr) Isomères et épimères 42 d'analogues d'ester de rapmycine, procédés de fabrication et d'utilisation correspondante
JP2007231016A (ja) テトラゾール含有ラパマイシン類似体のエピマーおよび異性体、同化合物の製造法および使用法
EP3330269B1 (fr) Composés hétérocycliques en tant qu'inhibiteurs de la biosynthèse d'acides gras pour des infections bactériennes
EP2826780A1 (fr) Dérivés de thieno[2,3-d]pyridazine et leur utilisation thérapeutique pour l'inhibition de la protéine kinase
US20150051242A1 (en) Rafamycin analogs and methods for making same
AU2002354465B2 (en) Thiadiazoline derivative
US5561137A (en) Thio-heterocyclic macrolactam immunomodulators
HU222575B1 (hu) Rapamicin-karbamát-származékok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
US6121257A (en) Sulfamate containing macrocyclic immunomodulators
JP2006500398A (ja) 良性及び悪性の腫瘍疾患を処置するためのジソラゾール及びその誘導体を含有している医薬
MXPA00002976A (en) Tetrazole-containing rapamycin analogs with shortened half-lives

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20141104

FZDE Dead

Effective date: 20161130